Page values for "Bromazolam"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Bromazolam
brand	`String`	(none, never marketed)
structure	`File`	File:Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position). Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
classes	List of `String`, delimiter: `,`	Designer benzodiazepine • Triazolobenzodiazepine • Sedative-Hypnotic • Research material
mechanism	`String`	Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
uses	`String`	No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
starting_dose	`String`	No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
preparations	`String`	Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
fda_max	`String`	N/A (never approved)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral • sublingual • intranasal; rectal and IV reported.
onset	`String`	~20–40 min PO; faster sublingual/intranasal.
duration	`String`	6–10 h subjective; full pharmacologic effect considerably longer.
halflife	`String`	Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
bioavailability	`String`	Not formally characterized in humans.
pregnancy	`String`	Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case.
legal	`String`